Article List
List all articles in the database by earliest discovery_date
GET /articles/?page=2
{ "count": 36953, "next": "http://api.gregory-ms.com/articles/?page=3", "previous": "http://api.gregory-ms.com/articles/", "results": [ { "article_id": 296842, "title": "A Rare Cause of Pediatric Facial Paralysis: Facial Colliculus Syndrome Secondary to Multiple Sclerosis Plaque", "summary": "<div><p>Ear Nose Throat J. 2025 Jun 13:1455613251349344. doi: 10.1177/01455613251349344. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40514191/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1BcJI_Rc2aE63Ua-t3gl15SmXX-8TV87zIWQkV8W1THnDMqUZe&fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414\">40514191</a> | DOI:<a href=\"https://doi.org/10.1177/01455613251349344\">10.1177/01455613251349344</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/40514191/?fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414", "published_date": "2025-06-13T10:00:00Z", "sources": [ "PubMed for MS" ], "teams": [ { "id": 1, "name": "Team Gregory", "slug": "team-gregory", "organization": 1 } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": "", "team_id": 1 } ], "publisher": "SAGE Publications", "container_title": "Ear, Nose & Throat Journal", "authors": [ { "author_id": 419920, "given_name": "Muhammet Sefa", "family_name": "Acar", "ORCID": "https://orcid.org/0000-0003-2675-1200", "country": null }, { "author_id": 419921, "given_name": "Gökhan", "family_name": "Polat", "ORCID": "https://orcid.org/0000-0002-9184-8730", "country": null } ], "discovery_date": "2025-06-14T23:32:55.964367Z", "article_subject_relevances": [], "doi": "10.1177/01455613251349344", "access": "restricted", "takeaways": "", "team_categories": [], "ml_predictions": [ { "id": 114487, "algorithm": "pubmed_bert", "model_version": "20250521_2", "probability_score": 0.03751567751169205, "predicted_relevant": false, "created_date": "2025-06-14T23:58:55.745255Z", "subject": 1 }, { "id": 114507, "algorithm": "lgbm_tfidf", "model_version": "20250524", "probability_score": 0.2205747638427738, "predicted_relevant": false, "created_date": "2025-06-14T23:58:57.604093Z", "subject": 1 }, { "id": 114527, "algorithm": "lstm", "model_version": "20250523_6", "probability_score": 0.4326629340648651, "predicted_relevant": false, "created_date": "2025-06-14T23:59:01.883663Z", "subject": 1 } ] }, { "article_id": 296841, "title": "Multiple sclerosis is associated with worse body composition across compartments: Results from a systematic review and meta-analysis", "summary": "<div><p>Mult Scler Relat Disord. 2025 May 25;101:106553. doi: 10.1016/j.msard.2025.106553. Online ahead of print.</p><p><b>ABSTRACT</b></p><p>BACKGROUND: There is conflicting evidence regarding specific differences in body composition (i.e., body fat, lean, and bone) between people with multiple sclerosis (MS) and non-MS controls. The objective of this meta-analysis was twofold: (1) quantify overall and compartment-specific differences in body composition between people with MS and controls; and (2) identify individual and disease-specific moderators of any differences in body composition between groups.</p><p>METHODS: A search of five electronic databases (MEDLINE, EMBASE, Cochrane Central, CINAHL, and Scopus) was performed by an information specialist.</p><p>RESULTS: Overall, 180 effects were derived from 37 studies, 155 (86.1 %) of which were negative, with a mean effect ∆ of -0.39 (95 %CI: -0.46, -0.32, Z = -10.86, p < 0.001) suggesting poorer overall body composition in people with MS. Disability status was significantly associated with overall effect size (β = 0.31, Z = 4.33, p < 0.0001); effects were significantly larger at higher disability levels. Regarding body fat, 55/61 (90.2 %) effects were negative, resulting in a mean effect ∆ of -0.32 (95 %CI: -0.43, -0.21, Z = -5.72, p < 0.001). With regards to lean tissue, 38/43 (88.4 %) effects were negative, with a mean effect ∆ of -0.38 (95 %CI: -0.56, -0.21, Z = -4.28, p < 0.001). Lastly, 62/76 (81.6 %) effects for bone mineral density were negative, with a mean effect ∆ of -0.44 (95 %CI: -0.55, -0.34, Z = -8.28, p < 0.001).</p><p>CONCLUSIONS: Current evidence supports poorer overall and compartment-specific body composition in people with MS, and this may be particularly relevant at higher disability. Strategies for managing body composition in MS should consider the need for maintaining lean mass and bone health, while managing obesity.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40513309/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1BcJI_Rc2aE63Ua-t3gl15SmXX-8TV87zIWQkV8W1THnDMqUZe&fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414\">40513309</a> | DOI:<a href=\"https://doi.org/10.1016/j.msard.2025.106553\">10.1016/j.msard.2025.106553</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/40513309/?fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414", "published_date": "2025-06-13T10:00:00Z", "sources": [ "PubMed for MS" ], "teams": [ { "id": 1, "name": "Team Gregory", "slug": "team-gregory", "organization": 1 } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": "", "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 380853, "given_name": "Lara A.", "family_name": "Pilutti", "ORCID": "https://orcid.org/0000-0002-3074-4903", "country": null }, { "author_id": 153224, "given_name": "Stephanie L.", "family_name": "Silveira", "ORCID": "http://orcid.org/0000-0002-1973-2119", "country": null }, { "author_id": 147866, "given_name": "Matthew P.", "family_name": "Herring", "ORCID": "http://orcid.org/0000-0002-6835-5321", "country": null }, { "author_id": 401081, "given_name": "Brenda", "family_name": "Jeng", "ORCID": "https://orcid.org/0000-0002-4522-1523", "country": null }, { "author_id": 244459, "given_name": "Thomas", "family_name": "Edwards", "ORCID": null, "country": null }, { "author_id": 163225, "given_name": "Katie L.J.", "family_name": "Cederberg", "ORCID": "http://orcid.org/0000-0001-5693-9293", "country": null }, { "author_id": 419919, "given_name": "Karine", "family_name": "Fournier", "ORCID": null, "country": null }, { "author_id": 380308, "given_name": "Robert W.", "family_name": "Motl", "ORCID": "https://orcid.org/0000-0002-5894-2290", "country": null } ], "discovery_date": "2025-06-14T23:32:51.821893Z", "article_subject_relevances": [], "doi": "10.1016/j.msard.2025.106553", "access": "restricted", "takeaways": "There is conflicting evidence regarding differences in body composition between people with MS and non-MS controls. 180 effects were derived from 37 studies, 155 of which were negative. Disability status was significantly associated with overall effect size.", "team_categories": [], "ml_predictions": [ { "id": 114488, "algorithm": "pubmed_bert", "model_version": "20250521_2", "probability_score": 0.018058141693472862, "predicted_relevant": false, "created_date": "2025-06-14T23:58:55.745278Z", "subject": 1 }, { "id": 114508, "algorithm": "lgbm_tfidf", "model_version": "20250524", "probability_score": 0.5777578297500973, "predicted_relevant": false, "created_date": "2025-06-14T23:58:57.604162Z", "subject": 1 }, { "id": 114528, "algorithm": "lstm", "model_version": "20250523_6", "probability_score": 0.041493698954582214, "predicted_relevant": false, "created_date": "2025-06-14T23:59:01.883697Z", "subject": 1 } ] }, { "article_id": 296840, "title": "Preventive and therapeutic effects of Tanshinone IIA on spinal cord injury without radiographic abnormality by regulating microglial phenotype polarization", "summary": "<div><p>Int Immunopharmacol. 2025 Jun 12;161:115086. doi: 10.1016/j.intimp.2025.115086. Online ahead of print.</p><p><b>ABSTRACT</b></p><p>Spinal cord injury without radiographic abnormality (SCIWORA) occurs in patients with cervical spinal stenosis (CSS) following minor trauma, often leading to significant neurological deficits. While surgical decompression reduces SCIWORA risk, some patients are ineligible or reluctant to undergo surgery. Consequently, reducing the risk of SCIWORA in the absence of surgical intervention and optimizing spinal cord function recovery remain pivotal challenges. This study explores the potential of Tanshinone IIA (TIIA) in preventing and treating SCIWORA by modulating microglial polarization and attenuating neuroinflammation. Asymptomatic CSS was induced in Sprague-Dawley rats by implanting hydrogels into the spinal canal for four weeks, followed by mild cervical trauma using the NYU Impactor. Rats were divided into sham, SCIWORA, prevention, and prevention + treatment groups. Preventive administration of TIIA significantly alleviated motor and histological damage, notably reducing glial scar formation and neuronal, myelin, and microvascular degeneration associated with SCIWORA. TIIA also inhibited the activation of pro-inflammatory M1 microglia while promoting the expansion of anti-inflammatory M2 microglia. Continued TIIA treatment after SCIWORA further enhanced motor function recovery, improved spinal cord tissue repair, provided ongoing protection to neurons, myelin, and microvasculature, reduced glial scar formation, modulated microglial polarization, inhibited NF-κB signaling pathway activation, and reduced neuroinflammation. These findings suggest that TIIA may serve as a non-surgical strategy to mitigate SCIWORA risk and promote recovery after SCIWORA in rats.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40513327/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1BcJI_Rc2aE63Ua-t3gl15SmXX-8TV87zIWQkV8W1THnDMqUZe&fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414\">40513327</a> | DOI:<a href=\"https://doi.org/10.1016/j.intimp.2025.115086\">10.1016/j.intimp.2025.115086</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/40513327/?fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414", "published_date": "2025-06-13T10:00:00Z", "sources": [ "PubMed for MS" ], "teams": [ { "id": 1, "name": "Team Gregory", "slug": "team-gregory", "organization": 1 } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": "", "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "International Immunopharmacology", "authors": [ { "author_id": 358424, "given_name": "Luchun", "family_name": "Xu", "ORCID": null, "country": null }, { "author_id": 358425, "given_name": "Yukun", "family_name": "Ma", "ORCID": null, "country": null }, { "author_id": 330941, "given_name": "Guozheng", "family_name": "Jiang", "ORCID": null, "country": null }, { "author_id": 391079, "given_name": "Zheng", "family_name": "Cao", "ORCID": null, "country": null }, { "author_id": 400997, "given_name": "Jiawei", "family_name": "Song", "ORCID": null, "country": null }, { "author_id": 400996, "given_name": "Yushan", "family_name": "Gao", "ORCID": null, "country": null }, { "author_id": 400998, "given_name": "Guanlong", "family_name": "Wang", "ORCID": null, "country": null }, { "author_id": 400999, "given_name": "Jiaojiao", "family_name": "Fan", "ORCID": null, "country": null }, { "author_id": 330943, "given_name": "Yongdong", "family_name": "Yang", "ORCID": null, "country": null }, { "author_id": 276094, "given_name": "Xing", "family_name": "Yu", "ORCID": null, "country": null } ], "discovery_date": "2025-06-14T23:32:47.701167Z", "article_subject_relevances": [], "doi": "10.1016/j.intimp.2025.115086", "access": "restricted", "takeaways": "Spinal cord injury without radiographic abnormality (SCIWORA) occurs in patients with cervical spinal stenosis following minor trauma. Tanshinone IIA (TIIA) was found to prevent and treat SCI WORA by modulating microglial polarization and attenuating neuroinflammation.", "team_categories": [], "ml_predictions": [ { "id": 114489, "algorithm": "pubmed_bert", "model_version": "20250521_2", "probability_score": 0.984563946723938, "predicted_relevant": true, "created_date": "2025-06-14T23:58:55.745299Z", "subject": 1 }, { "id": 114509, "algorithm": "lgbm_tfidf", "model_version": "20250524", "probability_score": 0.9687252980866582, "predicted_relevant": true, "created_date": "2025-06-14T23:58:57.604199Z", "subject": 1 }, { "id": 114529, "algorithm": "lstm", "model_version": "20250523_6", "probability_score": 0.9916444420814514, "predicted_relevant": true, "created_date": "2025-06-14T23:59:01.883733Z", "subject": 1 } ] }, { "article_id": 296839, "title": "Integrative exome sequencing and machine learning identify MICB and interferon pathway genes as contributors to SSc risk", "summary": "<div><p>Ann Rheum Dis. 2025 Jun 12:S0003-4967(25)00967-7. doi: 10.1016/j.ard.2025.05.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p>OBJECTIVES: Systemic sclerosis (SSc) is a complex autoimmune disease with both known and unidentified genetic contributors. While genome-wide association studies (GWAS) have implicated multiple loci, many reside in noncoding regions. We aimed to identify novel protein-coding variants and pathogenic pathways using exome sequencing (ES) integrated with an Evolutionary Action-Machine Learning (EAML) framework, single-cell RNA sequencing (scRNA-seq), and expression quantitative trait locus (eQTL) analysis.</p><p>METHODS: GWAS was conducted in 2,559 SSc cases and 893 controls of Caucasian ancestry, with replication in 9,846 cases and 18,333 controls of European ancestry. EAML prioritized genes with high-impact missense variants predictive of disease. Public scRNA-seq data from SSc and control skin biopsies were analyzed to localize gene expression across cell types. Whole blood eQTL data were used to identify regulatory effects of risk variants.</p><p>RESULTS: A novel SSc risk locus at MICB (rs2516497, P = 3.66 × 10<sup>-13</sup>) was identified and replicated. EAML highlighted 284 genes enriched in interferon signaling. scRNA-seq localized MICB and NOTCH4 to fibroblasts and endothelial cells, while HLA class II genes were enriched in macrophages and fibroblasts. eQTL analysis confirmed regulatory effects at MICB, NOTCH4, and other prioritized genes, linking SSc-associated variants to transcriptional dysregulation.</p><p>CONCLUSIONS: This integrative genomic study identifies novel risk loci and mechanistic pathways in SSc, highlighting MICB, NOTCH4, and interferon-related genes. The findings provide insight into the cellular and regulatory architecture of SSc and support the utility of combining ES, machine learning, scRNA-seq, and eQTL data in complex disease genetics.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40514331/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1BcJI_Rc2aE63Ua-t3gl15SmXX-8TV87zIWQkV8W1THnDMqUZe&fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414\">40514331</a> | DOI:<a href=\"https://doi.org/10.1016/j.ard.2025.05.009\">10.1016/j.ard.2025.05.009</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/40514331/?fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414", "published_date": "2025-06-13T10:00:00Z", "sources": [ "PubMed for MS" ], "teams": [ { "id": 1, "name": "Team Gregory", "slug": "team-gregory", "organization": 1 } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": "", "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "Annals of the Rheumatic Diseases", "authors": [ { "author_id": 419912, "given_name": "Shamika", "family_name": "Ketkar", "ORCID": "https://orcid.org/0000-0001-8799-0729", "country": null }, { "author_id": 358519, "given_name": "Hongzheng", "family_name": "Dai", "ORCID": "http://orcid.org/0000-0002-0103-876X", "country": null }, { "author_id": 358522, "given_name": "Lindsay", "family_name": "Burrage", "ORCID": "http://orcid.org/0000-0002-5108-8861", "country": null }, { "author_id": 419913, "given_name": "David", "family_name": "Murdock", "ORCID": "https://orcid.org/0000-0002-8536-3091", "country": null }, { "author_id": 419914, "given_name": "Brian", "family_name": "Dawson", "ORCID": null, "country": null }, { "author_id": 393386, "given_name": "Marialbert", "family_name": "Acosta-Herrera", "ORCID": "https://orcid.org/0000-0002-9868-6535", "country": null }, { "author_id": 393385, "given_name": "Martin", "family_name": "Kerick", "ORCID": "https://orcid.org/0000-0002-6298-4514", "country": null }, { "author_id": 322316, "given_name": "Javier", "family_name": "Martin", "ORCID": null, "country": null }, { "author_id": 419915, "given_name": "Kevin", "family_name": "Wilhelm", "ORCID": null, "country": null }, { "author_id": 419916, "given_name": "Jennifer Kay", "family_name": "Asmussen", "ORCID": "https://orcid.org/0000-0002-9280-0333", "country": null }, { "author_id": 419917, "given_name": "Olivier", "family_name": "Lichtarge", "ORCID": "https://orcid.org/0000-0003-4057-7122", "country": null }, { "author_id": 326737, "given_name": "Regeneron Genetics", "family_name": "Center", "ORCID": null, "country": null }, { "author_id": 181807, "given_name": "Shervin", "family_name": "Assassi", "ORCID": "http://orcid.org/0000-0002-8059-9978", "country": null }, { "author_id": 328556, "given_name": "Maureen D.", "family_name": "Mayes", "ORCID": "http://orcid.org/0000-0001-5070-2535", "country": null }, { "author_id": 419918, "given_name": "Brendan H.", "family_name": "Lee", "ORCID": "https://orcid.org/0000-0001-8573-4211", "country": null } ], "discovery_date": "2025-06-14T23:32:42.206859Z", "article_subject_relevances": [], "doi": "10.1016/j.ard.2025.05.009", "access": "restricted", "takeaways": "Systemic sclerosis (SSc) is a complex autoimmune disease with both known and unknown genetic contributors. Systemic sclerosis risk locus at MICB (rs2516497, P = 3.66 × 10-13) was identified and replicated. EAML highlighted 284 genes enriched in interferon signaling. ScRNA-seq localized MICB and NOTCH4 to fibroblasts and endothelial cells. HLA class II genes were enriched in macrophages", "team_categories": [], "ml_predictions": [ { "id": 114490, "algorithm": "pubmed_bert", "model_version": "20250521_2", "probability_score": 0.03173170983791351, "predicted_relevant": false, "created_date": "2025-06-14T23:58:55.745319Z", "subject": 1 }, { "id": 114510, "algorithm": "lgbm_tfidf", "model_version": "20250524", "probability_score": 0.48022722195153456, "predicted_relevant": false, "created_date": "2025-06-14T23:58:57.604232Z", "subject": 1 }, { "id": 114530, "algorithm": "lstm", "model_version": "20250523_6", "probability_score": 0.020361462607979774, "predicted_relevant": false, "created_date": "2025-06-14T23:59:01.883771Z", "subject": 1 } ] }, { "article_id": 296838, "title": "Validation of the self-report quantified Tuberous Sclerosis Complex-Associated Neuropsyciatric Disorders Checklist (TAND-SQ)", "summary": "<jats:title>Abstract</jats:title>\n<jats:sec>\n<jats:title>Background</jats:title>\n<jats:p>Tuberous Sclerosis Complex (TSC) is a rare multi-system genetic disorder characterised by benign growths in multiple body systems. TSC-Associated Neuropsychiatric Disorders (TAND) are very common in individuals with TSC, but families often struggle to access appropriate clinical care. To address this gap, the new TAND-SQ Checklist allows individuals with TSC or their caregivers to self-report and quantify characteristics of TAND. The 33 items make up seven natural TAND clusters and an eighth cluster reflecting psychosocial difficulties in individuals with TSC and their caregivers. Respondents rate items as having <jats:italic>ever</jats:italic> been present to generate cluster scores (CS), and rate item <jats:italic>severity</jats:italic> (over the last month) on a 10-point scale to generate cluster severity scores (CSS<jats:sub>mean</jats:sub>) and a total TAND severity score (TTSS<jats:sub>mean</jats:sub>). The purpose of this study was to determine the reliability and validity of the CS, CSS<jats:sub>mean</jats:sub> and TTSS<jats:sub>mean</jats:sub> of the TAND-SQ.</jats:p>\n</jats:sec>\n<jats:sec>\n<jats:title>Methods</jats:title>\n<jats:p>A descriptive group design was used. Two convenience samples with existing clinical data were recruited from the TSC Alliance Natural History Database (NHD) in the USA (n = 69), and from the Developmental Synaptopathies Consortium Rare Diseases Clinical Research Network (RDCRN) study based at Boston and Cincinnati Children's Hospitals (n = 23), totalling 92 participants.</jats:p>\n</jats:sec>\n<jats:sec>\n<jats:title>Results</jats:title>\n<jats:p>Analyses showed good internal consistency for CS (Cronbach’s alphas: 0.67–0.89) and CSS<jats:sub>mean</jats:sub> (0.76–0.95) with the exception of the eat/sleep cluster. Within the TAND-SQ, most CS and all CSS<jats:sub>mean</jats:sub> were significantly correlated to corresponding self-reported clinical diagnoses, and the TTSS<jats:sub>mean</jats:sub> was significantly correlated to a global self-rating of TAND burden (ρ = 0.75; <jats:italic>p</jats:italic> < .001). Significant correlations were observed between the CS and CSS<jats:sub>mean</jats:sub> and a range of relevant standardised behavioural measures in the RDCRN cohort. The TTSS<jats:sub>mean</jats:sub> was significantly correlated with global measures of adaptive behaviour (ρ = − 0.75; <jats:italic>p</jats:italic> < .001) and emotional/behavioural difficulties (ρ = 0.71; <jats:italic>p</jats:italic> = .001). All CS were significantly correlated with corresponding diagnoses of autism, ADHD, anxiety disorder, depressive disorder, scholastic difficulties, and neuropsychological difficulties where reported in the RDCRN and NHD cohorts.</jats:p>\n</jats:sec>\n<jats:sec>\n<jats:title>Conclusions</jats:title>\n<jats:p>Findings provide support for the reliability and validity of the CS, CSS<jats:sub>mean</jats:sub> and TTSS<jats:sub>mean</jats:sub> of the TAND-SQ and support their use in clinical decision-making for TAND management and in further research.</jats:p>\n</jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/40514711/?fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414", "published_date": "2025-06-13T10:00:00Z", "sources": [ "PubMed for MS" ], "teams": [ { "id": 1, "name": "Team Gregory", "slug": "team-gregory", "organization": 1 } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": "", "team_id": 1 } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Orphanet Journal of Rare Diseases", "authors": [ { "author_id": 419895, "given_name": "Nola", "family_name": "Chambers", "ORCID": "https://orcid.org/0000-0001-7008-472X", "country": null }, { "author_id": 419896, "given_name": "Tosca-Marie", "family_name": "Heunis", "ORCID": "https://orcid.org/0000-0001-7644-5231", "country": null }, { "author_id": 419897, "given_name": "Sugnet", "family_name": "Gardner-Lubbe", "ORCID": "https://orcid.org/0000-0003-2762-9944", "country": null }, { "author_id": 419898, "given_name": "Jamie K.", "family_name": "Capal", "ORCID": "https://orcid.org/0000-0002-7579-375X", "country": null }, { "author_id": 419899, "given_name": "Stacey", "family_name": "Bissell", "ORCID": "https://orcid.org/0000-0003-0701-3392", "country": null }, { "author_id": 419900, "given_name": "Anna W.", "family_name": "Byars", "ORCID": "https://orcid.org/0000-0002-3929-6107", "country": null }, { "author_id": 419901, "given_name": "Sebastián", "family_name": "Cukier", "ORCID": "https://orcid.org/0000-0002-1497-4709", "country": null }, { "author_id": 419902, "given_name": "Peter E.", "family_name": "Davis", "ORCID": "https://orcid.org/0000-0001-5796-6015", "country": null }, { "author_id": 262029, "given_name": "Jennifer", "family_name": "Flinn", "ORCID": null, "country": null }, { "author_id": 419903, "given_name": "Tanjala T.", "family_name": "Gipson", "ORCID": "https://orcid.org/0000-0002-6903-743X", "country": null }, { "author_id": 419904, "given_name": "J. Chris", "family_name": "Kingswood", "ORCID": "https://orcid.org/0000-0001-8794-9857", "country": null }, { "author_id": 419905, "given_name": "Aubrey J.", "family_name": "Kumm", "ORCID": "https://orcid.org/0000-0002-9472-7539", "country": null }, { "author_id": 262036, "given_name": "Eva", "family_name": "Schoeters", "ORCID": null, "country": null }, { "author_id": 251444, "given_name": "Catherine", "family_name": "Smith", "ORCID": null, "country": null }, { "author_id": 262037, "given_name": "Shoba", "family_name": "Srivastava", "ORCID": null, "country": null }, { "author_id": 262038, "given_name": "Megumi", "family_name": "Takei", "ORCID": null, "country": null }, { "author_id": 419906, "given_name": "Stephanie", "family_name": "Vanclooster", "ORCID": "https://orcid.org/0000-0002-5642-7711", "country": null }, { "author_id": 419907, "given_name": "Agnies M.", "family_name": "van Eeghen", "ORCID": "https://orcid.org/0000-0001-8149-8645", "country": null }, { "author_id": 419908, "given_name": "Robert", "family_name": "Waltereit", "ORCID": "https://orcid.org/0000-0002-5338-2765", "country": null }, { "author_id": 419909, "given_name": "Darcy A.", "family_name": "Krueger", "ORCID": "https://orcid.org/0000-0002-7250-7391", "country": null }, { "author_id": 393822, "given_name": "Mustafa", "family_name": "Sahin", "ORCID": "https://orcid.org/0000-0001-7044-2953", "country": null }, { "author_id": 419910, "given_name": "Liesbeth", "family_name": "De Waele", "ORCID": "https://orcid.org/0000-0001-7126-575X", "country": null }, { "author_id": 379903, "given_name": "Anna", "family_name": "Jansen", "ORCID": "https://orcid.org/0000-0002-3835-2824", "country": null }, { "author_id": 419911, "given_name": "Petrus J.", "family_name": "de Vries", "ORCID": "https://orcid.org/0000-0002-8915-1571", "country": null } ], "discovery_date": "2025-06-14T23:32:30.094278Z", "article_subject_relevances": [], "doi": "10.1186/s13023-025-03642-2", "access": "restricted", "takeaways": null, "team_categories": [], "ml_predictions": [ { "id": 114491, "algorithm": "pubmed_bert", "model_version": "20250521_2", "probability_score": 0.009328493848443031, "predicted_relevant": false, "created_date": "2025-06-14T23:58:55.745339Z", "subject": 1 }, { "id": 114511, "algorithm": "lgbm_tfidf", "model_version": "20250524", "probability_score": 0.39026845643914065, "predicted_relevant": false, "created_date": "2025-06-14T23:58:57.604267Z", "subject": 1 }, { "id": 114531, "algorithm": "lstm", "model_version": "20250523_6", "probability_score": 0.0015970856184139848, "predicted_relevant": false, "created_date": "2025-06-14T23:59:01.883804Z", "subject": 1 } ] }, { "article_id": 296837, "title": "Granulocyte-macrophage colony-stimulating factor may contribute to spondyloarthritis development in HLA-B27 transgenic rat by affecting conventional dendritic cells function", "summary": "<jats:title>Abstract</jats:title>\n<jats:sec>\n<jats:title>Background</jats:title>\n<jats:p>Spondyloarthritis (SpA) is a chronic inflammatory disorder with axial and peripheral manifestations. A strong association between HLA-B27 and SpA has been known for more than 50 years. Remarkably, HLA-B27 and human β2-microglubulin transgenic rats (B27 rat) develop manifestations recapitulating SpA, referred to as rat SpA. Antigen-presenting cells such as dendritic cells (DC) and CD4 T cells are mandatory to develop rat SpA. Serum levels of granulocyte macrophage-colony stimulating factor (GM-CSF), a key growth factor for DC generation and functions, are significantly increased during SpA. Conventional (c)DCs can be divided in two subsets implicated either in immune tolerance (cDC1) or in adaptive immune responses induction (cDC2). In this study, we aimed to determine the influence of GM-CSF on cDC subsets functions linked to T cell activation and differentiation, in the B27 rat model.</jats:p>\n</jats:sec>\n<jats:sec>\n<jats:title>Methods</jats:title>\n<jats:p>cDC subsets were isolated from spleens of B27 and nontransgenic (NTG) rats, primed with GM-CSF and tested for their ability to support CD4h T cell differentiation. RNA sequencing was performed on GM-CSF-primed cDC subsets.</jats:p>\n</jats:sec>\n<jats:sec>\n<jats:title>Results</jats:title>\n<jats:p>GM-CSF-primed cDC2 from B27 rat were strong inducers of TNF-producing proinflammatory CD4<jats:sup>+</jats:sup> T cells. In contrast, whereas control cDC1 required GM-CSF to support T cell proliferation, HLA-B27<jats:sup>+</jats:sup> cDC1 primed with GM-CSF failed to do so. RNA sequencing analysis demonstrated that HLA-B27 expression promoted endoplasmic reticulum stress and unfolded protein response in both cDC subsets. In addition, HLA-B27 expression promoted inflammatory cytokine synthesis by cDC2 and a signature interfering with regulation of cell adhesion and activation in cDC1.</jats:p>\n</jats:sec>\n<jats:sec>\n<jats:title>Conclusion</jats:title>\n<jats:p>Altogether, our study reveals a dual role of GM-CSF during SpA. In one hand, GM-CSF promotes proinflammatory functions of cDC2. On the other hand, GM-CSF is required for cDC1 to induce T cell proliferation, and those functions are blunted by HLA-B27 expression.</jats:p>\n</jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/40514729/?fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414", "published_date": "2025-06-13T10:00:00Z", "sources": [ "PubMed for MS" ], "teams": [ { "id": 1, "name": "Team Gregory", "slug": "team-gregory", "organization": 1 } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": "", "team_id": 1 } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Arthritis Research & Therapy", "authors": [ { "author_id": 419890, "given_name": "Amel Ait Ali", "family_name": "Said", "ORCID": null, "country": null }, { "author_id": 243760, "given_name": "Chiara", "family_name": "Rizzo", "ORCID": null, "country": null }, { "author_id": 419891, "given_name": "Hendrick Mambu", "family_name": "Mambueni", "ORCID": null, "country": null }, { "author_id": 419892, "given_name": "Félicie", "family_name": "Costantino", "ORCID": null, "country": null }, { "author_id": 419893, "given_name": "Maxime", "family_name": "Breban", "ORCID": null, "country": null }, { "author_id": 419894, "given_name": "Simon", "family_name": "Glatigny", "ORCID": null, "country": null } ], "discovery_date": "2025-06-14T23:32:26.748004Z", "article_subject_relevances": [], "doi": "10.1186/s13075-025-03586-9", "access": "restricted", "takeaways": "Spondyloarthritis (SpA) is a chronic inflammatory disorder with axial and peripheral manifestations. Serum levels of granulocyte macrophage-colony stimulating factor (GM-CSF) are significantly increased during SpA. GM- CSF promotes proinflammatory functions of cDC2 and cDC1, while HLA-B27 expression promotes inflammatory cytokine synthesis and inhibits cell adhesion.", "team_categories": [], "ml_predictions": [ { "id": 114492, "algorithm": "pubmed_bert", "model_version": "20250521_2", "probability_score": 0.23360221087932587, "predicted_relevant": false, "created_date": "2025-06-14T23:58:55.745359Z", "subject": 1 }, { "id": 114512, "algorithm": "lgbm_tfidf", "model_version": "20250524", "probability_score": 0.849696579649881, "predicted_relevant": true, "created_date": "2025-06-14T23:58:57.604303Z", "subject": 1 }, { "id": 114532, "algorithm": "lstm", "model_version": "20250523_6", "probability_score": 0.4154835045337677, "predicted_relevant": false, "created_date": "2025-06-14T23:59:01.883835Z", "subject": 1 } ] }, { "article_id": 296836, "title": "Pharmacokinetic-pharmacodynamic modelling in a clinical pilot study of rituximab in multiple sclerosis: Towards personalized dosing interval", "summary": "<div><p>Br J Clin Pharmacol. 2025 Jun 14. doi: 10.1002/bcp.70136. Online ahead of print.</p><p><b>ABSTRACT</b></p><p>AIMS: Rituximab (RTX) is used off-label for relapsing-remitting multiple sclerosis, although dosing regimens vary. Observational data suggest the standard 6-month interval may be extended and individualized. We aimed to develop a pharmacokinetic-pharmacodynamic (PKPD) model to describe patient-specific RTX concentrations and CD19+ lymphocyte counts.</p><p>METHODS: Thirteen treatment-naïve patients initiated RTX treatment with 1000 mg intravenously. Blood samples were collected at 6 time points during the following 6 months. RTX concentrations and CD19+ lymphocyte counts were used to compare different PKPD using the nonlinear mixed-effects software Monolix.</p><p>RESULTS: Initial pharmacokinetics of RTX could be described by a 1-compartment model with nonlinear target-mediated elimination of rituximab. Introduction of CD19+ lymphocyte counts as a pharmacodynamic marker resulted in comparable performance of a 1-compartment and a 2-compartment model and can provide descriptions of RTX concentrations and CD19+ lymphocyte counts in individual patients. In both models, nonspecific clearance (CL) contributes approximately 10 times more to the overall elimination than target-mediated clearance (k<sub>deg,1</sub>; CL [1/day] = 0.075 ± 0.035 [median 0.061], k<sub>deg,1</sub> [mm<sup>-3</sup>/day] = 0.125 ± 0.311 [median 0.007] and CL [1/day] = 0.036 ± 0.027 [median 0.026], k<sub>deg,1</sub> [mm<sup>-3</sup>/day] = 0.004 ± 0.002 [median 0.003]).</p><p>CONCLUSIONS: The PKPD models were able to describe the data both in patients exhibiting enduring CD19+ lymphocyte depletion and in patients exhibiting signs of early CD19+ lymphocyte repopulation. Additional data are required to validate and advance models for prediction of repopulation dynamics and, eventually, individualized RTX dosing.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40515509/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1pq-4TZ0w1pBinCOGHI102WNbZ7J_Sy6TyOPWav10SQEpUpQS6&fc=20250602171614&ff=20250614193356&v=2.18.0.post9+e462414\">40515509</a> | DOI:<a href=\"https://doi.org/10.1002/bcp.70136\">10.1002/bcp.70136</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/40515509/?fc=20250602171614&ff=20250614193356&v=2.18.0.post9+e462414", "published_date": "2025-06-14T10:00:00Z", "sources": [ "PubMed for MS", "PubMed | DMTs" ], "teams": [ { "id": 1, "name": "Team Gregory", "slug": "team-gregory", "organization": 1 }, { "id": 2, "name": "CRIEM", "slug": "criem", "organization": 4 } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": "", "team_id": 1 }, { "id": 6, "subject_name": "Disease Modifying Treatments", "description": "# Query used \r\n```sql\r\n(\"interferon\" OR \"rebif\" OR \"avonex\" OR \"extavia\" OR \"betaferon\" OR \"plegrid\" OR\r\n\"glatiramer acetate\" OR \"copaxone\" OR\r\n\"dimethyl fumarate\" OR \"tecfidera\" OR\r\n\"diroximel fumarate\" OR \"vumerity\" OR\r\n\"teriflunomide\" OR \"aubagio\" OR\r\n\"cladribine\" OR \"mavenclad\" OR\r\n\"fingolimod\" OR \"gilenya\" OR\r\n\"siponimod\" OR \"mayzent\" OR\r\n\"ozanimod\" OR \"zeposia\" OR\r\n\"ponesimod\" OR \"ponvory\" OR\r\n\"S1PR\" OR \"S1P\" OR \"sphingosine 1 phosphate receptor modulator\" OR\r\n\"natalizumab\" OR \"tysabri\" OR \"tyruko\" OR\r\n\"anti-VLA4\" OR \"anti-integrin\" OR \"anti-migratory\" OR\r\n\"ofatumumab\" OR \"kesimpta\" OR\r\n\"ocrelizumab\" OR \"ocrevus\" OR\r\n\"ublituximab\" OR \"briumvi\" OR\r\n\"B-cell depleting therapies\" OR \"BCDT\" OR \"anti-CD20\" OR\r\n\"rituximab\" OR\r\n\"alemtuzumab\" OR \"lemtrada\" OR\r\n\"tolebrutinib\" OR\r\n\"Bruton's tyrosine kinase inhibitors\" OR \"BTKi\" OR\r\n\"chimeric antigen receptor T-cells\" OR \"CAR-T\" OR\r\n\"chimeric autoantibody receptor T-cells\" OR \"CAAR-T\" OR\r\n\"regulatory chimeric antigen receptor T-cells\" OR \"CAR-T reg\" OR\r\n\"autologous hematopoietic stem cell transplantation\" OR \"aHSCT\" OR\r\n\"opicinumab\" OR\r\n\"ibudilast\")\r\n```\r\n\r\n# RSS link\r\n\r\n<https://pubmed.ncbi.nlm.nih.gov/rss/search/1pq-4TZ0w1pBinCOGHI102WNbZ7J_Sy6TyOPWav10SQEpUpQS6/?limit=15&utm_campaign=pubmed-2&fc=20250602171614>", "team_id": 2 } ], "publisher": null, "container_title": null, "authors": [], "discovery_date": "2025-06-14T23:32:21.839206Z", "article_subject_relevances": [], "doi": "10.1002/bcp.70136", "access": null, "takeaways": "Rituximab (RTX) is used off-label for relapsing-remitting multiple sclerosis. Thirteen treatment-naïve patients were given 1000 mg intravenously. Blood samples were collected at 6 time points during the following 6 months. CD19+ lymphocyte counts were used to compare different PKPD models.", "team_categories": [ { "id": 28, "category_name": "Rituximab", "category_description": "Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer.", "category_slug": "rituximab", "category_terms": [ "Rituximab", "rituxan" ] } ], "ml_predictions": [ { "id": 114493, "algorithm": "pubmed_bert", "model_version": "20250521_2", "probability_score": 0.06902884691953659, "predicted_relevant": false, "created_date": "2025-06-14T23:58:55.745379Z", "subject": 1 }, { "id": 114513, "algorithm": "lgbm_tfidf", "model_version": "20250524", "probability_score": 0.6254290440594796, "predicted_relevant": false, "created_date": "2025-06-14T23:58:57.604338Z", "subject": 1 }, { "id": 114533, "algorithm": "lstm", "model_version": "20250523_6", "probability_score": 0.630022406578064, "predicted_relevant": false, "created_date": "2025-06-14T23:59:01.883866Z", "subject": 1 } ] }, { "article_id": 296835, "title": "Hypoxia Exposure Promotes Th17 Cell Differentiation Through Activin A‐<scp>PKM2</scp> Axis to Exacerbate Autoimmune and Autoinflammatory Diseases", "summary": "<jats:title>ABSTRACT</jats:title><jats:p>Hypobaric hypoxia, a defining feature of high‐altitude environments, induces significant physiological and pathological changes in the human body. Under the disrupted homeostasis and altered disease microenvironment caused by high‐altitude conditions, the immune system exhibits distinct responses compared to those observed in low‐altitude settings. Our study investigates the impact of hypobaric hypoxia on autoimmune and autoinflammatory diseases and explores the underlying molecular mechanisms. Using an environmental simulation chamber, we subjected mouse models of experimental autoimmune encephalomyelitis (EAE) and psoriasis to hypobaric hypoxia, simulating conditions at an altitude of 6000 m. Pathological analysis and flow cytometry demonstrated exacerbated disease severity and elevated Th17 cell levels. Given the established role of Th17 cells as key effector cells in autoimmune and autoinflammatory diseases, we further investigated their response through transcriptomic comparisons under normoxic and hypoxic conditions, which identified Activin A as a central regulator of hypoxia‐induced Th17 cell differentiation. In mice exposed to hypobaric hypoxia, pharmacological inhibition of Activin A significantly alleviated the severity of psoriasis. Western blotting, flow cytometry, and immunofluorescence analyses confirmed that under normoxic conditions, Activin A stimulation amplified the pathogenic Th17 cell molecular program, whereas blockade of p‐PKM2 or ERK signaling suppressed this effect. Collectively, our findings uncover a molecular mechanism whereby hypoxia‐triggered Activin A release drives pathogenic Th17 differentiation via the ERK pathway, promoting p‐PKM2 nuclear translocation and subsequent transcriptional activation of Th17 master regulators and effector cytokines. This study provides a theoretical foundation for understanding immune dysregulation at high altitudes and offers potential therapeutic strategies for mitigating high‐altitude‐associated immune disorders.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/40515525/?fc=20240915071900&ff=20250614193156&v=2.18.0.post9+e462414", "published_date": "2025-06-14T10:00:00Z", "sources": [ "PubMed for MS" ], "teams": [ { "id": 1, "name": "Team Gregory", "slug": "team-gregory", "organization": 1 } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": "", "team_id": 1 } ], "publisher": "Wiley", "container_title": "The FASEB Journal", "authors": [ { "author_id": 419884, "given_name": "Yuhui", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 409351, "given_name": "Mengting", "family_name": "He", "ORCID": null, "country": null }, { "author_id": 277329, "given_name": "Jie", "family_name": "Xu", "ORCID": null, "country": null }, { "author_id": 419885, "given_name": "Jiayao", "family_name": "Liu", "ORCID": null, "country": null }, { "author_id": 419886, "given_name": "Chenxi", "family_name": "Xiao", "ORCID": null, "country": null }, { "author_id": 419887, "given_name": "Yajie", "family_name": "Hu", "ORCID": null, "country": null }, { "author_id": 419888, "given_name": "Honghong", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 321876, "given_name": "Jun", "family_name": "Chang", "ORCID": null, "country": null }, { "author_id": 419889, "given_name": "Xinhua", "family_name": "Liu", "ORCID": null, "country": null } ], "discovery_date": "2025-06-14T23:32:17.577795Z", "article_subject_relevances": [], "doi": "10.1096/fj.202500719R", "access": "restricted", "takeaways": "Hypobaric hypoxia induces significant physiological and pathological changes in the human body. The study provides a theoretical foundation for understanding immune dysregulation at high altitudes and offers potential therapeutic strategies for mitigating high altitude-associated immune disorders.", "team_categories": [], "ml_predictions": [ { "id": 114494, "algorithm": "pubmed_bert", "model_version": "20250521_2", "probability_score": 0.6930869817733765, "predicted_relevant": false, "created_date": "2025-06-14T23:58:55.745401Z", "subject": 1 }, { "id": 114514, "algorithm": "lgbm_tfidf", "model_version": "20250524", "probability_score": 0.977458478490918, "predicted_relevant": true, "created_date": "2025-06-14T23:58:57.604374Z", "subject": 1 }, { "id": 114534, "algorithm": "lstm", "model_version": "20250523_6", "probability_score": 0.42590954899787903, "predicted_relevant": false, "created_date": "2025-06-14T23:59:01.883899Z", "subject": 1 } ] }, { "article_id": 296834, "title": "'Should natalizumab be used despite JC virus positivity? Yes'", "summary": "<div><p>Mult Scler. 2025 Jun 14:13524585251346374. doi: 10.1177/13524585251346374. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40515591/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1pq-4TZ0w1pBinCOGHI102WNbZ7J_Sy6TyOPWav10SQEpUpQS6&fc=20250602171614&ff=20250614193356&v=2.18.0.post9+e462414\">40515591</a> | DOI:<a href=\"https://doi.org/10.1177/13524585251346374\">10.1177/13524585251346374</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/40515591/?fc=20250602171614&ff=20250614193356&v=2.18.0.post9+e462414", "published_date": "2025-06-14T10:00:00Z", "sources": [ "PubMed for MS", "PubMed | DMTs" ], "teams": [ { "id": 1, "name": "Team Gregory", "slug": "team-gregory", "organization": 1 }, { "id": 2, "name": "CRIEM", "slug": "criem", "organization": 4 } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": "", "team_id": 1 }, { "id": 6, "subject_name": "Disease Modifying Treatments", "description": "# Query used \r\n```sql\r\n(\"interferon\" OR \"rebif\" OR \"avonex\" OR \"extavia\" OR \"betaferon\" OR \"plegrid\" OR\r\n\"glatiramer acetate\" OR \"copaxone\" OR\r\n\"dimethyl fumarate\" OR \"tecfidera\" OR\r\n\"diroximel fumarate\" OR \"vumerity\" OR\r\n\"teriflunomide\" OR \"aubagio\" OR\r\n\"cladribine\" OR \"mavenclad\" OR\r\n\"fingolimod\" OR \"gilenya\" OR\r\n\"siponimod\" OR \"mayzent\" OR\r\n\"ozanimod\" OR \"zeposia\" OR\r\n\"ponesimod\" OR \"ponvory\" OR\r\n\"S1PR\" OR \"S1P\" OR \"sphingosine 1 phosphate receptor modulator\" OR\r\n\"natalizumab\" OR \"tysabri\" OR \"tyruko\" OR\r\n\"anti-VLA4\" OR \"anti-integrin\" OR \"anti-migratory\" OR\r\n\"ofatumumab\" OR \"kesimpta\" OR\r\n\"ocrelizumab\" OR \"ocrevus\" OR\r\n\"ublituximab\" OR \"briumvi\" OR\r\n\"B-cell depleting therapies\" OR \"BCDT\" OR \"anti-CD20\" OR\r\n\"rituximab\" OR\r\n\"alemtuzumab\" OR \"lemtrada\" OR\r\n\"tolebrutinib\" OR\r\n\"Bruton's tyrosine kinase inhibitors\" OR \"BTKi\" OR\r\n\"chimeric antigen receptor T-cells\" OR \"CAR-T\" OR\r\n\"chimeric autoantibody receptor T-cells\" OR \"CAAR-T\" OR\r\n\"regulatory chimeric antigen receptor T-cells\" OR \"CAR-T reg\" OR\r\n\"autologous hematopoietic stem cell transplantation\" OR \"aHSCT\" OR\r\n\"opicinumab\" OR\r\n\"ibudilast\")\r\n```\r\n\r\n# RSS link\r\n\r\n<https://pubmed.ncbi.nlm.nih.gov/rss/search/1pq-4TZ0w1pBinCOGHI102WNbZ7J_Sy6TyOPWav10SQEpUpQS6/?limit=15&utm_campaign=pubmed-2&fc=20250602171614>", "team_id": 2 } ], "publisher": null, "container_title": null, "authors": [], "discovery_date": "2025-06-14T23:32:16.581283Z", "article_subject_relevances": [], "doi": "10.1177/13524585251346374", "access": null, "takeaways": "", "team_categories": [ { "id": 5, "category_name": "Natalizumab", "category_description": "", "category_slug": "natalizumab", "category_terms": [ "natalizumab", "tysabri" ] } ], "ml_predictions": [ { "id": 114495, "algorithm": "pubmed_bert", "model_version": "20250521_2", "probability_score": 0.11652342975139618, "predicted_relevant": false, "created_date": "2025-06-14T23:58:55.745421Z", "subject": 1 }, { "id": 114515, "algorithm": "lgbm_tfidf", "model_version": "20250524", "probability_score": 0.49795765563185534, "predicted_relevant": false, "created_date": "2025-06-14T23:58:57.604409Z", "subject": 1 }, { "id": 114535, "algorithm": "lstm", "model_version": "20250523_6", "probability_score": 0.008187538012862206, "predicted_relevant": false, "created_date": "2025-06-14T23:59:01.883934Z", "subject": 1 } ] }, { "article_id": 296833, "title": "Diagnostic uncertainty in the era of biosimilar natalizumab—The case for harmonizing anti-JCV antibody testing", "summary": "<div><p>Mult Scler. 2025 Jun;31(7):751-753. doi: 10.1177/13524585251346658. Epub 2025 Jun 14.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40515640/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1pq-4TZ0w1pBinCOGHI102WNbZ7J_Sy6TyOPWav10SQEpUpQS6&fc=20250602171614&ff=20250614193356&v=2.18.0.post9+e462414\">40515640</a> | DOI:<a href=\"https://doi.org/10.1177/13524585251346658\">10.1177/13524585251346658</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/40515640/?fc=20250602171614&ff=20250614193356&v=2.18.0.post9+e462414", "published_date": "2025-06-14T10:00:00Z", "sources": [ "PubMed for MS", "PubMed | DMTs" ], "teams": [ { "id": 1, "name": "Team Gregory", "slug": "team-gregory", "organization": 1 }, { "id": 2, "name": "CRIEM", "slug": "criem", "organization": 4 } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": "", "team_id": 1 }, { "id": 6, "subject_name": "Disease Modifying Treatments", "description": "# Query used \r\n```sql\r\n(\"interferon\" OR \"rebif\" OR \"avonex\" OR \"extavia\" OR \"betaferon\" OR \"plegrid\" OR\r\n\"glatiramer acetate\" OR \"copaxone\" OR\r\n\"dimethyl fumarate\" OR \"tecfidera\" OR\r\n\"diroximel fumarate\" OR \"vumerity\" OR\r\n\"teriflunomide\" OR \"aubagio\" OR\r\n\"cladribine\" OR \"mavenclad\" OR\r\n\"fingolimod\" OR \"gilenya\" OR\r\n\"siponimod\" OR \"mayzent\" OR\r\n\"ozanimod\" OR \"zeposia\" OR\r\n\"ponesimod\" OR \"ponvory\" OR\r\n\"S1PR\" OR \"S1P\" OR \"sphingosine 1 phosphate receptor modulator\" OR\r\n\"natalizumab\" OR \"tysabri\" OR \"tyruko\" OR\r\n\"anti-VLA4\" OR \"anti-integrin\" OR \"anti-migratory\" OR\r\n\"ofatumumab\" OR \"kesimpta\" OR\r\n\"ocrelizumab\" OR \"ocrevus\" OR\r\n\"ublituximab\" OR \"briumvi\" OR\r\n\"B-cell depleting therapies\" OR \"BCDT\" OR \"anti-CD20\" OR\r\n\"rituximab\" OR\r\n\"alemtuzumab\" OR \"lemtrada\" OR\r\n\"tolebrutinib\" OR\r\n\"Bruton's tyrosine kinase inhibitors\" OR \"BTKi\" OR\r\n\"chimeric antigen receptor T-cells\" OR \"CAR-T\" OR\r\n\"chimeric autoantibody receptor T-cells\" OR \"CAAR-T\" OR\r\n\"regulatory chimeric antigen receptor T-cells\" OR \"CAR-T reg\" OR\r\n\"autologous hematopoietic stem cell transplantation\" OR \"aHSCT\" OR\r\n\"opicinumab\" OR\r\n\"ibudilast\")\r\n```\r\n\r\n# RSS link\r\n\r\n<https://pubmed.ncbi.nlm.nih.gov/rss/search/1pq-4TZ0w1pBinCOGHI102WNbZ7J_Sy6TyOPWav10SQEpUpQS6/?limit=15&utm_campaign=pubmed-2&fc=20250602171614>", "team_id": 2 } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 388525, "given_name": "Tjalf", "family_name": "Ziemssen", "ORCID": "https://orcid.org/0000-0001-8799-8202", "country": null }, { "author_id": 169913, "given_name": "Diego", "family_name": "Centonze", "ORCID": "http://orcid.org/0000-0002-8390-8545", "country": "IT" } ], "discovery_date": "2025-06-14T23:32:15.103519Z", "article_subject_relevances": [], "doi": "10.1177/13524585251346658", "access": "restricted", "takeaways": "", "team_categories": [ { "id": 5, "category_name": "Natalizumab", "category_description": "", "category_slug": "natalizumab", "category_terms": [ "natalizumab", "tysabri" ] } ], "ml_predictions": [ { "id": 114496, "algorithm": "pubmed_bert", "model_version": "20250521_2", "probability_score": 0.034996144473552704, "predicted_relevant": false, "created_date": "2025-06-14T23:58:55.745440Z", "subject": 1 }, { "id": 114516, "algorithm": "lgbm_tfidf", "model_version": "20250524", "probability_score": 0.5438235544418712, "predicted_relevant": false, "created_date": "2025-06-14T23:58:57.604443Z", "subject": 1 }, { "id": 114536, "algorithm": "lstm", "model_version": "20250523_6", "probability_score": 0.004970279987901449, "predicted_relevant": false, "created_date": "2025-06-14T23:59:01.883967Z", "subject": 1 } ] } ] }